Ulcerative colitis is a chronic inflammatory disease of the colon mucosa which always starts in the rectum; depending on how far the disease extends proximally, it is classified as proctitis, proctosigmoiditis, left-sided, subtotal or total pancolitis (sometimes with backwash ileitis). The cardinal symptoms are peranal hemorrhage, diarrhea and evacuations of small stool quantities with tenesmus. Ulcerative colitis is an intermittent disease with a high risk of recurrence, and remission can take from weeks to years. The diagnosis is based on the clinical picture and the endoscopic findings; additional microbiological examinations are indicated for the differential diagnosis in acute diarrhea. Medical therapy includes 5-ASA and SASP preparations, beclomethasone, budesonide and prednisone. Immunosuppressive therapy is indicated in steroid-refractory and chronic active disease; therapy options for severe episodes are corticosteroids, cyclosporine A, azathioprine, tacrolimus, infliximab and adalimumab. Potential complications include toxic megacolon, colon perforation, hemorrhage, thromboembolic complications, osteoporosis, CMV superinfection, intestinal scarring, colon carcinoma and primary sclerosing cholangitis. Surgical therapy is indicated for severe treatment-resistant episodes, megacolon, perforation, refractory bleeding, dysplasia of the colon mucosa or chronic active disease. Under adequate therapy, the mortality nowadays amounts to <1–2%.
Read full abstract